Evaluation of drug interactions with P-glycoprotein in drug discovery:: In vitro assessment of the potential for drug-drug interactions with P-glycoprotein

被引:92
|
作者
Hochman, JH [1 ]
Yamazaki, M [1 ]
Ohe, T [1 ]
Lin, JH [1 ]
机构
[1] Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA
关键词
D O I
10.2174/1389200023337559
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The pharmacological effects of a drug are highly dependent on the absorption, metabolism, elimination, and distribution of the drug. In the past few years it has become apparent that transport proteins play a major role in regulating the distribution, elimination and metabolism of some drugs. As a consequence of our new understanding of the influence of transport proteins on the pharmacokinetic and pharmacodynamic behavior of drugs, increasing attention has been focused on the potential for drug-drug interactions arising from interactions with drug transport proteins. The efflux transporter P-glycoprotein (P-gp) has received the most attention with regard to its role in restricting drug absorption and distribution and as a potential source for variability in drug pharmacokinetics and pharmacodynamics. This review will focus on the evaluation of drug candidates to assess the potential for drug interactions at the level of P-gp. We will discuss the role of P-gp in drug disposition, the biochemistry of P-gp efflux as it relates to model systems to study drug interactions with P-gp, and the implementation of P-gp assay models within the drug discovery process.
引用
收藏
页码:257 / 273
页数:17
相关论文
共 50 条
  • [1] The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions
    Yu, DK
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (12): : 1203 - 1211
  • [2] Psychotropic Drug-Drug Interactions Involving P-Glycoprotein
    Akamine, Yumiko
    Yasui-Furukori, Norio
    Ieiri, Ichiro
    Uno, Tsukasa
    CNS DRUGS, 2012, 26 (11) : 959 - 973
  • [3] Does inhibition of P-glycoprotein lead to drug-drug interactions?
    Balayssac, D
    Authier, N
    Cayre, A
    Coudore, F
    TOXICOLOGY LETTERS, 2005, 156 (03) : 319 - 329
  • [4] Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions
    Lund, Marie
    Petersen, Tonny Studsgaard
    Dalhoff, Kim Peder
    DRUGS, 2017, 77 (08) : 859 - 883
  • [5] Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions
    Nicolas, Jean-Marie
    Chanteux, Hugues
    Nicolai, Johan
    Brouta, Frederic
    Viot, Delphine
    Rosseels, Marie-Luce
    Gillent, Eric
    Bonnaillie, Pierre
    Mathy, Francois-Xavier
    Long, Jeff
    Helmer, Eric
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 142
  • [6] Computer Evaluation of Drug Interactions with P-Glycoprotein
    Lagunin, A. A.
    Gloriozova, T. A.
    Dmitriev, A. V.
    Volgina, N. E.
    Poroikov, V. V.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2013, 154 (04) : 521 - 524
  • [7] Computer Evaluation of Drug Interactions with P-Glycoprotein
    A. A. Lagunin
    T. A. Gloriozova
    A. V. Dmitriev
    N. E. Volgina
    V. V. Poroikov
    Bulletin of Experimental Biology and Medicine, 2013, 154 : 521 - 524
  • [8] Cardiovascular Ion Channel Inhibitor Drug-Drug Interactions with P-glycoprotein
    Ledwitch, Kaitlyn V.
    Roberts, Arthur G.
    AAPS JOURNAL, 2017, 19 (02): : 409 - 420
  • [9] Study Models of Drug-Drug Interactions Involving P-Glycoprotein: The Potential Benefit of P-Glycoprotein Modulation at the Kidney and Intestinal Levels
    Veiga-Matos, Jessica
    Morales, Ana I.
    Prieto, Marta
    Remiao, Fernando
    Silva, Renata
    MOLECULES, 2023, 28 (22):
  • [10] Cardiovascular Ion Channel Inhibitor Drug-Drug Interactions with P-glycoprotein
    Kaitlyn V. Ledwitch
    Arthur G. Roberts
    The AAPS Journal, 2017, 19 : 409 - 420